Emtricitabine is a fluorinated derivative of lamivudine.
Atripla is emtricitabine, efavirenz and tenofovir disoproxil; Complera is emtricitabine, rilpivirine and tenofovir disoproxil; Descovy is emtricitabine and tenofovir alafenamide; Truvada is emtricitabine and tenofovir disoproxil.
See also separate profiles for emtricitabine in combination with cobicistat, elvitegravir and tenofovir disoproxil or tenofovir alafenamide.
- TRADE NAMES: Atripla (Gilead); Complera (Gilead); Descovy (Gilead); Emtriva (Gilead); Truvada (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Nucleoside analog reverse transcriptase inhibitor
- HALF-LIFE: ~10 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Ganciclovir, Lamivudine, Ribavirin, Valganciclovir
- See adverse reactions attributed to class:
LACTIC ACIDOSIS / SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of emtricitabine with tenofovir disoproxil in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
